Scholars Central

Conference abstract

Creation of highly efficient recombinant viral vectors for development of prime-boost vaccines: Matrix protein gene variants of two antigenically distinct serotypes of vesicular stomatitis virus are ideal vaccine vectors

Authors: Chil-Yong Kang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In order to induce the maximum immune responses by vaccination, the priming recombinant viral vector should be antigenically distinct from the boost vaccine vector. A priming vaccine vector will most likely induce neutralizing antibodies which will neutralize the boosting vaccine vector if one uses the same vector for the prime-boost. One of the rhabdo viruses, the vesicular stomatitis virus (VSV), offers the ideal system for prime-boost vaccine vectors. We have generated safer and more highly efficient recombinant VSV vaccine vectors using two antigenically distinct Indiana serotype (VSVInd) and New Jersey serotype (VSVNJ). The M51R mutation in the M gene of VSVInd was combined with a temperature sensitive mutation of the VSVInd Orsay tsO23 for priming vaccine vector [designated as rVSVInd (GML)]. In addition, we have generated two new VSVNJ vaccine vectors by combining M48R+M51R mutation with G22E and L110F mutations in the M gene of VSVNJ, [designated as rVSVNJ (GMM) and VSVNJ(GMML)] for boosting. The combined mutations of G21E/M51R/L111A in the M protein of VSVInd [rVSVInd(GML)] significantly reduced the burst size of the virus by up to 10,000 fold at a semi-permissive temperature of 37°C without affecting the level of protein expression. The BHK21 cells and human neuroblastoma, SH-SY5Y cells infected with rVSVInd (GML), rVSVNJ(GMM) and rVSVNJ(GMML) showed significantly reduced cytopathic effects in vitro at 37°C, and mice injected with one million infectious particles of the viruses into the brain showed no neurological dysfunctions or any other adverse effects. In contrast, only one thousand wild-type VSVInd killed mice within four days. To examine the CD8+ T cell and B cell responses against the protein of interest expressed from the new rVSV vectors, we generated rVSVs with HIV-1gag, pol and/or env genes. From the various vaccination regimens tested in mice, priming with rVSVInd (GML)-HIV-1gag, pol, and/or env and boosting with rVSVNJ(GMM)-HIV-1gag, pol, and/or env and rVSVNJ(GMML)-HIV-1gag, pol, and/or env induced the strongest CD8+ T cell immune responses against HIV-1 Gag, Pol, and Env proteins. The same vaccination regimen also induced strong humoral immune responses against HIV-1 Gag and Env proteins in mice. The best humoral immune responses against HIV-1 Gag and Env proteins were induced when two serotypes of rVSV were alternated for prime and boost vaccination. Increasing vaccination doses of rVSVInd (GML)-HIV-1 gag, pol, and/or env, rVSVNJ (GMM)-HIV-1gag, pol, and/or env and rVSVNJ (GMML)-HIV-1gag, pol and/or env induced stronger immune responses against HIV-1 Gag, Pol and Env proteins in mice. As a boost vaccine vector, rVSVNJ (GMM), it induced better cellular and humoral immune responses against HIV-1 Gag and Env proteins compared to rVSVNJ (GMML) with the same vaccine dose. This is our unique platform technology and is useful for development of not only viral diseases but also bacterial diseases and even parasitic diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Chil-Yong Kang”